Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to determine efficacy and safety of Aumolertinib plus Icotinib as a first-line therapy in EGFR mutated NSCLC with brain metastases patients

Next Previous
Trial Profile

A study to determine efficacy and safety of Aumolertinib plus Icotinib as a first-line therapy in EGFR mutated NSCLC with brain metastases patients

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aumolertinib (Primary) ; Gefitinib (Primary) ; Icotinib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 16 Sep 2022 New trial record
  • 09 Aug 2022 Protocol was amended to include patients received alternating monthly cycles of TKI monotherapy.
  • 09 Aug 2022 Results (n=12) reporting ORR and AEs from phase I portion of this trial presented at the 2022 World Conference on Lung Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top